NovaPure components adhere to scientific, risk-mitigating Quality by Design (QbD) principles for dimensional control and consistency, vision inspection and visible particulate control, and particle specification. The new components are specifically designed for 3mL cartridges often used in autoinjectors and other drug delivery devices. They incorporate West's quality enhancements: Westar pharmaceutical wash and sterilization, FluroTec barrier film, and a comprehensive data package, and are designed for sensitive biologics.
The SmartDose portfolio offers patients an easy-to-use method for home-based drug administration. The SmartDose Gen. II 10mL drug delivery system adheres to the patient's body, so patients can remain hands-free during the injection, which may range from minutes to hours. The company has now completed the development work to enable up to 10mL of medication injection and is ready for commercialization.
"Our customers face a number of demands from increasing regulations and requirements, to evolving patient needs, to an ever-changing healthcare landscape. Our goal is to simplify their journey and work by their side to support them with products, services and solutions. We aim to speed their development and to help ensure a continuous supply to the market of important therapies which drive better patient outcomes," said Karen Flynn, senior vice president and chief commercial officer, West. "The launch of our NovaPure 3mL Cartridge components line and the enhancements to our SmartDose platform are the first of many upcoming product launches and updates we'll be announcing in the coming months to address specific issues we know our customers are facing as they work to bring innovative, new injectable medicines to market."
Visit West at CPhI booth 111F62.